Purpose: Dysregulation of miRNAs plays an important role in the malignancy of different tumors including chordoma. Expression of miR-149-3p was earlier reported to be downregulated in chordoma tissue. However, its biological role remains to be unrevealed in chordoma, especially in spinal chordoma. Methods: Expression of miR-149-3p and Smad3 was detected by RT-qPCR and Western blot. Chordoma malignancy was evaluated by cell proliferation, migration, invasion, and apoptosis using MTT assay, transwell assay, flow cytometry analyzing apoptosis rate, and Western blot-determined expression of Bcl-2, Bax, and cleaved caspase 3, respectively. The target binding between miR-149-3p and Smad3 was predicted by TargetScan Human website and confirmed by luciferase reporter assay and RNA immunoprecipitation. Xenograft tumors were generated, and expression of miR-149-3p and Smad3 was investigated in vivo. Results: miR-149-3p was downregulated in spinal chordoma tissues and cells, and its overexpression promoted chordoma cell apoptosis and inhibited proliferation, migration, and invasion in U-CH1 and MUG-Chor1 cells. Unexpectedly, Smad3 was a downstream target of miR-149-3p and negatively correlated with miR-149-3p expression in chordoma tissues. Besides, Smad3 was upregulated in chordoma tissues and its silencing had a similar effect as miR-149-3p overexpression in U-CH1 and MUG-Chor1 cells. Moreover, Smad3 upregulation could partially reverse the tumor-suppressive effect of miR-149-3p in chordoma cells. In vivo, the tumorigenesis of U-CH1 and MUG-Chor1 cells was impaired by upregulated miR-149-3p through decreasing Smad3 expression. Conclusion: miR-149-3p could serve as a tumor suppressor in spinal chordoma through targeting and downregulating Smad3.
Introduction
Chordoma is a mesenchymal tissue tumor and accounts for 1-4% of all bone tumors. 1 Arising from embryonic remnants of notochord, chordoma is characterized with high metastasis to bone, lung, and liver, and high recurrence in spite of its slow growth and low incidence. 2 Usually, this tumor predominantly attacks older male adults in clivus and sacrum. 3 Clinically, surgical resection is the first choice for the effective treatment of chordoma, followed by high-dose radiotherapy. 4, 5 However, patients are still vulnerable to relapse after surgery. Therefore, it is urgently needed to explore the molecular pathogenesis underlying chordoma, and thus providing novel promising therapeutic targets. Recent studies indicated that the growth of chordoma was possibly relying on multiple mechanisms, including genetic and epigenetic modifications. [6] [7] [8] The major epigenetic changes include DNA methylation, histone modification, and post-transcriptional regulation controlled by noncoding RNAs including microRNAs (miRNAs). miRNAs are a class of highly conserved small noncoding RNAs with approximately 22 nucleotides. Mechanically, the complementary binding of miRNAs to target messenger RNAs (mRNAs) results in the degradation of mRNA or translation inhibition. 9 Dysregulation of miRNAs plays important roles in tumor initiation and progression, 10 and miRNAs take an indispensable part in different tumors including chordoma. 11 Recently, differentially expressed miRNA patterns have been screened in chordoma tissues and cells. 12, 13 Moreover, several miRNAs such as miRNA-140-3p, 14 miRNA-1237-3p, 15 and miRNA-155 16 are identified to be markers correlated with prognosis in chordoma.
Besides, altered miRNA profile is also discovered in chordoma cancer stem-like cells (CSCs) which are related to tumorigenesis, recurrence, and resistance in cancers. 17 It is well documented that dysregulation of miRNAs affects cancer initiation and progression through altering mRNA expression. For example, miRNA-31, miRNA-148a, and miRNA-222-3p modulate the cell viability, cell cycle, apoptosis, and differentiation by targeting and downregulating RDX and MET, DNMT1 and DNMT3B, and TRPS1, BIRC5, and KIT.
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Integrated miRNA-mRNA profile analysis reveals that miRNA-149-3p (miR-149-3p), together with miRNA663a, miRNA-1908, miRNA-2861, and miRNA-3185, is complicated with MAPK pathways which are consistently enriched in the chordoma tissues. 18 Previous studies have suggested that miR-149-3p is a novel cancer-related miRNA and participates in various cancers, including bladder cancer, 19 pancreatic cancer, 20 and gastric cancer. 21 The cell proliferation, migration, and invasion tend to be suppressed by miR-149-3p. Furthermore, miR-149-3p serves as a biomarker for diagnosis 22 and prognosis 23 of cancers. However, the biological functions of miR-149-3p in chordoma have not been illuminated yet, especially in spinal chordoma. miR-149-3p has been reported to target several genes such as S100A4, 19 forkhead box protein M1 (FOXM1), 24 Akt1, 20 and Wnt-1. 21 Therefore, in the present study, we detected the expression of miR-149-3p in spinal chordoma tissues. The effects of miR-149-3p on chordoma cell proliferation, apoptosis, migration, and invasion were investigated, as well as its downstream target gene. 
Materials And Reagents Chordoma Tissue Samples

Human Nucleus Pulposus Cell Isolation and Cell Culture
Nucleus pulposus cells were isolated from healthy nucleus pulposus tissues of patients with disc herniation, described above. The tissues were sequentially digested at 37°C by 0.25% trypsin solution for 30 mins and then 0.2% type II collagenase for 4 hrs. After removing tissue debris, the digest cells were cultured in DMEM (HyClone, Logan, UT, USA) containing 20% FBS (HyClone). The human chordoma cell lines U-CH1 (CRL-3217) and MUG-Chor1 (CRL-3219) were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and were cultured in Iscove's Modified Dulbecco's Medium (IMDM) and RPMI-1640 (HyClone) at a ratio of 4:1 supplemented with 10% FBS (HyClone), 1% penicillin-streptomycin (HyClone), and 1% L-glutamine (HyClone). All cells were incubated in a humidified incubator with a 5% CO 2 -95% air atmosphere at 37°C.
Cell Transfection
Plasmid pcDNA 3.1-Smad3, oligonucleotides including siRNA against Smad3 (siSmad3), miR-149-3p mimic, anti-miR-149-3p, and their negative controls were acquired 
Transwell Migration And Invasion Assay
For determination of the ability of migration and invasion, U-CH1 and MUG-Chor1 cells transfected or not were exposed with transwell assay. The transwell assays were performed in 24-well transwell chamber (8 μm pores; Corning, NY, USA) with matrigel-free (for migration) or matrigel-coated (for invasion) (BD Biosciences). U-CH1 and MUG-Chor1 (2 × 10 4 cells/mL) were resuspended into 200 μL of serum-free medium and plated in the upper chamber, and the lower chamber was filled with 500 µL complete medium containing 10% FBS. After the transwell system were stayed in 37°C for 24 hrs, the cells on the lower surface were stained with 0.1% crystal violet for 15 mins at room temperature, followed by being photographed and counted under a light microscope. Each transwell assay was repeated three times.
Flow Cytometry
The Human Smad3 3ʹ UTR fragment wild type (Smad3-wt) containing the potential binding sites of hsa-miR-149-3p and its corresponding mutant (Smad3-mut) were cloned by PCR methods into pmirGLO vector (Invitrogen). The Smad3-wt was replaced the CCCUCCC with GGGAGGG as the Smad3-mut. U-CH1 and MUG-Chor1 cells were cotransfected according to the following groups: Smad3-wt +miR-NC mimic (NC), Smad3-wt+miR-149-3p, Smad3-mut+NC, Smad3-mut+miR-149-3p. The pmirGLO vector itself provided a strong renilla luciferase signal acting as a control reporter for normalization. After 48 hr incubation, cells were collected to measure firefly and renilla luciferase activity using the dual-luciferase reporter assay system (Promega, Madison, WI, USA). The relative luciferase activity was the average of at least three independent transfections and was the ratio of firefly to renilla. All the transfection groups were performed in triplicate. RIP was performed with extracts from U-CH1 and MUG-Chor1 cells after transfection with miR-149-3p/NC. All the transfection groups were performed in triplicate. Magna RIP TM RNA-binding protein immunoprecipitation kit (Millipore, Bradford, MA, USA) was chosen to detect the expression of Smad3 from the samples bound to the Ago2 or IgG antibody. After washing, total RNAs were isolated with TRIzol and subjected to RT-qPCR assay. All operations obeyed the standard instructions.
Tumor Xenografts b is the shortest tumor axis); the mice were practiced with euthanasia on week 5 and the weight of tumors was evaluated with an electronic balance. Immediately, the xenograft tumors were flash-frozen in lipid nitrogen and stored in −80°C for further isolation of total RNA and protein.
Statistical Analyses
All data were shown as mean ± standard deviation. All statistical analyses were performed using SPSS software 21.0 (IBM, Armonk, NY, USA). Student's t test was used to determine the statistical significance between two groups in vitro and in vivo experiments. A two-tailed value of P<0.05 was considered statistically significant. The statistical association between expressions of miR-149-3p and Smad3 mRNA was evaluated with regression correlation analyses.
Results
miR-149-3p Was Downregulated In Spinal Chordoma Tissues And Its Overexpression Inhibited Chordoma Malignancy In Vitro
To assess the role of miR-149-3p in chordoma, we measured its expression in spinal chordoma tissues. As shown in Figure 1A , the expression level of miR-149-3p in spinal chordoma tissues was abundantly lower than nucleus pulposus tissues according to RT-qPCR results (2 −ΔΔCt values). The human chordoma cell lines U-CH1 and MUG-Chor1 were utilized to investigated biological functions of miR-149-3p dysregulation in chordoma. First, U-CH1 and MUG-Chor1 cells expressed lower basal level of miR-149-3p compared to human nucleus pulposus cells ( Figure 1B ) and were forced highly expressed miR-149-3p by transient transfection of miR-149-3p mimic (miR-149-3p), and miR-NC mimic (NC) transfection was the negative control group. The high transfection efficiency (more than 3.5-fold) was determined by analyzing miR-149-3p levels ( Figure 1C ). After transfection for 36 hrs, a series of functional experiments were carried out. Cell viability of U-CH1 and MUG-Chor1 cells was evaluated by MTT assay, and OD450 values were significantly decreased in the miR-149-3p group on 72 h ( Figure 1D ). Transwell assays were used to measure the ability of U-CH1 and MUG-Chor1 cell migration and invasion. As a result, numbers of migratory cells and invasive cells were descended when miR-149-3p overexpressed ( Figure 1E and F). Cell apoptosis was identified with flow cytometry and Western blot. As presented in Figure 1G , the apoptosis rate of U-CH1 and MUG-Chor1 cells after miR-149-3p transfection was distinctively elevated than the NC group. Meanwhile, the expression of apoptosis-related gene Bax and cleaved caspase 3 was promoted by ectopic expression of miR-149-3p, accompanied by inhibited Bcl-2 level ( Figure 1H ). These results demonstrated that miR-149-3p was downregulated in spinal chordoma tissues, and its overexpression could inhibit chordoma cell proliferation, migration, and invasion and promoted apoptosis in vitro, suggesting a suppressive role of miR-149-3p in spinal chordoma malignancy.
miR-149-3p Targeted And Downregulated Smad3 In Chordoma Cells
In this study, the regulatory relationship between miR-149-3p and Smad3 was investigated. According to the in silicon data on TargetScan Human, there was one putative miR-149-3p target site in 3ʹ UTR of Smad3 wild type (Smad3-wt) as represented in Figure 2A . Figure 2A , as well as the corresponding mutant (Smad3-mut). The sequences containing Smad3-wt and Smad3-mut were cloned into luciferase reporter plasmid pmirGLO, and relative luciferase activity of both was examined. U-CH1 and MUG-Chor1 cells were co-transfected with Smad3-wt/mut and miR-149-3p mimic or miR-NC mimic. As depicted in Figure 2B , relative luciferase activity of Smad3-wt was remarkably reduced in the presence of miR-149-3p mimic versus miR-NC mimic; however, there was no difference in Smad3-mut group. Moreover, RIP was launched to further confirm the target binding
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anti-GAPDH 37kDa between miR-149-3p and Smad3, and expression of Smad3 in RIP-Ago2 in U-CH1 and MUG-Chor1 cells was extremely enriched when overexpressed miR-149-3p ( Figure 2C ). Subsequently, the regulatory effect of miR-149-3p on Smad3 expression was detected. Protein expression level of Smad3 in U-CH1 and MUG-Chor1 cells was reduced when transfected with miR-149-3p mimic and increased when transfected with anti-miR-149-3p ( Figure 2D ). Besides, there existed an extremely significant (R 2 =0.739, P<o.oo1) negative correlation between expression levels of miR-149-3p and Smad3 mRNA in chordoma tissues ( Figure 2E ). These data illustrated that Smad3 served as a target gene for miR-149-3p and was negatively regulated by miR-149-3p.
Smad3 Was Upregulated In Spinal Chordoma Tissues And Its Silencing Suppressed Chordoma Malignancy In Vitro
To explore the expression of Smad3 in chordoma, tissues of spinal chordoma and nucleus pulposus were isolated. RT-qPCR results (2 −ΔΔCt values) showed the upregulation of Smad3 in spinal chordoma ( Figure 3A) . The functional roles of Smad3 dysregulation were determined in chordoma cells in vitro. U-CH1 and MUG-Chor1 cells were forced lowly expressed Smad3 by transient transfection of siSmad3, and transfection of scrambled siRNA (Scramble) was the negative control group. The high transfection efficiency (about 0.3-fold) was determined by analyzing Smad3 mRNA levels ( Figure 3B ). After transfection for 36 hrs in U-CH1 and MUG-Chor1 cells, cell proliferation was attenuated by siSmad3, as evidenced by MTT assay analyzing OD450 values for 72 hrs ( Figure 3C) ; the ability of cell motility was also decreased when transfected with siSmad3 as described by transwell migration and invasion assays ( Figure 3D and E); on the contrary, cell apoptosis was identified to be facilitated as demonstrated by higher apoptosis rate ( Figure 3F ), elevated levels of Bax and cleaved caspase 3, and lower Bcl-2 level ( Figure 3G ). These results indicated that Smad3 was upregulated in spinal chordoma tissues, and its silencing could suppress chordoma cell proliferation, migration, and invasion and promoted apoptosis in vitro, suggesting a suppressive role of Smad3 downregulation in spinal chordoma malignancy.
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Smad3 Upregulation Partially Reversed The Tumor-Suppressive Effect Of miR-149-3p In Chordoma Cells In Vitro
Next, we wondered whether miR-149-3p suppressed spinal chordoma malignancy through downregulating its target gene Smad3. To further figure it out, rescue experiments were performed. U-CH1 and MUG-Chor1 cells were co-transfected with miR-149-3p mimic and pcDNA-Smad3/vector. As Figure 4A presented, Smad3 protein expression was strongly inhibited by miR-149-3p and then rescued by ectopic expression of Smad3. Subsequently, the influence of ectopic Smad3 on the effect of miR-149-3p on chordoma malignancy was measured in vitro. The attenuated OD450 values for 72 hrs ( Figure 4B ) and numbers of migratory cells and invasive cells ( Figure 4C and D) induced by miR-149-3p mimic were significantly improved in the presence of pcDNA-Smad3. Inversely, miR-149-3p overexpression-mediated upregulation of apoptosis rate ( Figure 4E ), and the expression of Bax and cleaved caspase 3 ( Figure 4F ) was abolished by ectopic Smad3; Bcl-2 expression was lower when miR-149-3p sole transfection, which was reversed when simultaneous transfection of miR-149-3p mimic and pcDNA-Smad3 ( Figure 4F ). These data illuminated that Smad3 upregulation partially reversed the suppressive effect of miR-149-3p in spinal chordoma malignancy, implying miR-149-3p/Smad3 axis might underlie one of the pathogenesis of chordoma.
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Overexpression Of miR-149-3p Inhibited Tumorigenesis Of Chordoma Cells In Vivo
In order to verify the role of miR-149-3p on tumorigenesis, U-CH1 and MUG-Chor1 cells were stably expressed by miR-149-3p/NC mimic and then were injected into mice. As shown in Figure 5A , the tumors formed in both groups and the tumors in the miR-149-3p group were dramatically smaller and lighter than the NC group after inoculation for 4-5 weeks. Moreover, the expression of miR-149-3p was higher and Smad3 was lower in xenograft tumors induced by U-CH1 and MUG-Chor1 cells ( Figure 5B and C). These outcomes showed miR-149-3p overexpression inhibited the xenograft tumor growth, suggesting an association between miR-149-3p expression and in vivo proliferation capacity of chordoma cells.
Discussion
Dysregulated expression of miRNAs is frequently observed in chordoma compared to different types of control tissues: muscle, embryonic notochord, and nucleus pulposus.
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Acting as tumor suppressors or oncogenes, these miRNAs affect the initiation, development, and prognosis of chordoma. For example, miR-1 25 and miR-31 26 were consistently downregulated in chordoma, and restoration of them inhibited chordoma cell proliferation, migration, and invasion by targeting Slug and EZH2 in U-CH1 and JHC7 cells. anti-Smad3 42kDa
anti-GAPDH 37kDa miR-155 16 and miR-140-3p 14 expression in chordoma tissues was significantly elevated, and this expression correlated significantly with disease stage, metastasis, and poor outcomes; inhibition of miR-155 suppressed chordoma proliferation and the migratory and invasive activities in U-CH1 cells. 16 However, there is still very limited information about miRNAs in chordoma. In the present study, we confirmed whether expression of miR-149-3p was downregulated in chordoma and further investigated the role of miR-149-3p in regulating spinal chordoma malignancy, as well as confirming miR-149-3p/Smad3 axis in the pathogenesis of spinal chordoma.
To our best knowledge, this is the first to demonstrate the role of miR-149-3p in chordoma cells, even though its downregulation was early announced by Long et al. 18 We performed RT-qPCR assay to examine the altered expression level of miR-149 in spinal chordoma tissues and noticed that miR-149-3p was dramatically lower in spinal chordoma tissues versus nucleus pulposus tissues. Results from miRNA array assay analyzing and RT-qPCR validation showed that miR-149-3p, miR-663a, miR-1908, miR-2861, and miR-3185 were downregulated in chordoma tissue compared to notochord tissue and targeted to MAPK pathway-related mRNAs. 18 These data suggest that miR-149-3p may act as a tumor suppressor in chordoma. To further research the special biological functions of miR-149-3p in chordoma, we forced highly expressed miR-149-3p in human chordoma cell lines U-CH1 and MUG-Chor1 by transfection. Subsequently, a series of functional experiments were carried out and miR-149-3p overexpression suppressed chordoma cell proliferation, migration, and invasion and promoted apoptosis in vitro. Moreover, U-CH1 and MUG-Chor1 cells
anti-GAPDH 37kDa 20 Apoptosis rate and levels of Bax, Apaf-1, cleaved caspase-3/9, cleaved PARP, and cytochrome c release could be increased by miR-149-3p. Taken together, miR-149-3p could function as a widespread tumor suppressor in regulating cell proliferation, apoptosis, migration, invasion, and inflammation in different tumors. Next, we explored the mechanism of miR-149-3p in chordoma cells, and Smad3 was suggested to be a downstream target of miR-149-3p as confirmed by luciferase reporter assay and RIP. Smad3, a major transcription factor in transforming growth factor-β (TGF-β) signaling, plays critical roles in both tumor-suppressive and pro-oncogenic functions. A wide variety of biological processes such as cell cycle progression 28 and fibrosis, 29 as well as apoptosis, migration, and invasion 12, 30 have been declared to be altered by Smad3 expression. It also sheds light on the target association between Smad3 and miRNAs in tumors including miRNA-5195-3p 28 miRNA-145, 31 and miRNA-505-3p 32 In chordoma, miRNA-16-5p targeting Smad3 was declared to participate in cell proliferation, invasion, and metastasis in U-CH1 and U-CH2 cells. 12 However, there is no evidence to clarify the relationship between miR-149-3p and Smad3. In addition, the role of Smad3 in chordoma has not been well illustrated. Here, we demonstrated a novel miR-149-3p/Smad3 axis in regulating chordoma cell development. In brief, both of the studies observed a higher expression of Smad3 in chordoma tissues and cell lines, and a suppressive effect of Smad3 knockdown on proliferation, migration, and invasion in vitro through acting as a downstream target gene for miRNA. Whereas, they declared the biological role of Smad3 in U-CH1 and U-CH2 cells, and an inhibition of Smad3 knockdown on epithelial-mesenchymal transition (EMT); instead, we showed the effects of Smad3 in U-CH1 and MUG-Chor1 cells and a promotion of Smad3 knockdown on apoptosis. Besides acting as target gene for miRNA, Smad3 mRNA expression was demonstrated to be corrected with miR-16-5p 12 and miR-149-3p expression in chordoma tissues. Furthermore, we also discovered that silencing of Smad3 promoted apoptosis rate and expression of Bax and cleaved caspase3, accompanied by decreased Bcl-2 level. However, the contribution of Smad3 on EMT was left to be uncovered in this study, as well as the correlation between Smad3 expression and biological characteristics of chordoma. Additionally, whether Smad3 signaling pathways participated in spinal chordoma malignancy, especially in miR-149-3p role in spinal chordoma has been sealed still.
To summarize, we showed miR-149-3p was downregulated in spinal chordoma tissue, and its overexpression enhanced chordoma cell apoptosis and inhibited cell viability, migration, and invasion in vitro through directly downregulating Smad3. Besides, knockdown of Smad3 had a similar effect as overexpression of miR-149-3p in spinal chordoma malignancy. In vivo, the tumor growth of chordoma was impaired by upregulated miR-149-3p accompanied by low Smad3 expression level. Our research demonstrates a precise biological role of miR-149-3p, as well as the Smad3 in spinal chordoma. We also provide a novel target relationship between miR-149-3p and Smad3.
Conclusion
In summary, miR-149-3p could serve as a tumor suppressor in spinal chordoma through targeting and downregulating Smad3.
Abbreviations miRNAs, microRNAs; mRNAs, messenger RNAs; CSCs, cancer stem-like cells; FOXM1, forkhead box protein M1; IMDM, Iscove's Modified Dulbecco's Medium; FBS, fetal bovine serum; siSmad3, siRNA against Smad3; SD, standard deviation; TGF-β, transforming growth factor-β.
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